JP4749334B2 - 組換えアデノウイルス用パッケージング細胞 - Google Patents

組換えアデノウイルス用パッケージング細胞 Download PDF

Info

Publication number
JP4749334B2
JP4749334B2 JP2006530273A JP2006530273A JP4749334B2 JP 4749334 B2 JP4749334 B2 JP 4749334B2 JP 2006530273 A JP2006530273 A JP 2006530273A JP 2006530273 A JP2006530273 A JP 2006530273A JP 4749334 B2 JP4749334 B2 JP 4749334B2
Authority
JP
Japan
Prior art keywords
cells
cell
sequence
sequences
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006530273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507216A5 (enExample
JP2007507216A (ja
Inventor
ボーゲルズ ロナルド
ジャンス エムコ ハヴェンガ メンゾ
アドリアヌス セオドラス マリア ズエイドジースト デイヴィッド
Original Assignee
クルセル ホランド ベー ヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルセル ホランド ベー ヴェー filed Critical クルセル ホランド ベー ヴェー
Publication of JP2007507216A publication Critical patent/JP2007507216A/ja
Publication of JP2007507216A5 publication Critical patent/JP2007507216A5/ja
Application granted granted Critical
Publication of JP4749334B2 publication Critical patent/JP4749334B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2006530273A 2003-10-02 2004-10-04 組換えアデノウイルス用パッケージング細胞 Expired - Fee Related JP4749334B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/50679 2003-10-02
EP0350679 2003-10-02
PCT/EP2004/052428 WO2005033320A1 (en) 2003-10-02 2004-10-04 Packaging cells for recombinant adenovirus

Publications (3)

Publication Number Publication Date
JP2007507216A JP2007507216A (ja) 2007-03-29
JP2007507216A5 JP2007507216A5 (enExample) 2007-11-22
JP4749334B2 true JP4749334B2 (ja) 2011-08-17

Family

ID=34400432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530273A Expired - Fee Related JP4749334B2 (ja) 2003-10-02 2004-10-04 組換えアデノウイルス用パッケージング細胞

Country Status (15)

Country Link
US (2) US7816104B2 (enExample)
EP (1) EP1670925B1 (enExample)
JP (1) JP4749334B2 (enExample)
KR (1) KR101203817B1 (enExample)
CN (2) CN1863918B (enExample)
AU (1) AU2004278517B2 (enExample)
BR (1) BRPI0414670A (enExample)
CA (1) CA2538025C (enExample)
DK (1) DK1670925T3 (enExample)
EA (1) EA010924B1 (enExample)
HR (1) HRP20130616T1 (enExample)
IL (2) IL174489A (enExample)
NZ (1) NZ545501A (enExample)
SI (1) SI1670925T1 (enExample)
WO (1) WO2005033320A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1670925B1 (en) 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008134720A2 (en) * 2007-04-30 2008-11-06 Medtronic, Inc. Inert dna sequences for efficient viral packaging and methods of use
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
KR101427200B1 (ko) * 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
AP2014007993A0 (en) * 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
CN110832072B (zh) 2017-04-21 2023-11-07 真基因太科公司 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
CN108342362A (zh) * 2018-01-31 2018-07-31 武汉枢密脑科学技术有限公司 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines
WO2003031633A2 (de) * 2001-10-04 2003-04-17 Probiogen Ag Adenovirales vektorsystem
WO2005010146A2 (en) * 2003-07-03 2005-02-03 Cell Genesys, Inc. Adenoviral e1a/e1b complementing cell line

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889806A (en) * 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
FI972225A7 (fi) 1994-11-28 1997-07-16 Genetic Therapy Inc Vektorit kudosspesifistä replikaatiota varten
CA2206683A1 (en) 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
EP1445322B2 (en) * 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE289354T1 (de) 1999-04-15 2005-03-15 Crucell Holland Bv Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CA2812799C (en) 2001-07-04 2016-01-26 Chromagenics B.V. Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences
EP1670925B1 (en) 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines
WO2003031633A2 (de) * 2001-10-04 2003-04-17 Probiogen Ag Adenovirales vektorsystem
WO2005010146A2 (en) * 2003-07-03 2005-02-03 Cell Genesys, Inc. Adenoviral e1a/e1b complementing cell line

Also Published As

Publication number Publication date
US20100311172A1 (en) 2010-12-09
IL174489A (en) 2013-10-31
CN102174536B (zh) 2013-02-13
CN1863918A (zh) 2006-11-15
AU2004278517A1 (en) 2005-04-14
HRP20130616T1 (en) 2013-08-31
CN102174536A (zh) 2011-09-07
BRPI0414670A (pt) 2006-11-21
CN1863918B (zh) 2011-03-30
US20060183232A1 (en) 2006-08-17
IL227543A (en) 2015-08-31
HK1084974A1 (en) 2006-08-11
KR20060095557A (ko) 2006-08-31
CA2538025A1 (en) 2005-04-14
IL174489A0 (en) 2006-08-01
EP1670925A1 (en) 2006-06-21
AU2004278517B2 (en) 2010-04-01
KR101203817B1 (ko) 2012-11-23
DK1670925T3 (da) 2013-07-08
EP1670925B1 (en) 2013-05-01
US8114637B2 (en) 2012-02-14
SI1670925T1 (sl) 2013-10-30
NZ545501A (en) 2010-12-24
WO2005033320A1 (en) 2005-04-14
CA2538025C (en) 2012-07-17
EA010924B1 (ru) 2008-12-30
US7816104B2 (en) 2010-10-19
EA200600693A1 (ru) 2006-10-27
JP2007507216A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
US8114637B2 (en) Packaging cells for recombinant adenovirus
US7344883B2 (en) Complementing cell lines
Hardy et al. Construction of adenovirus vectors through Cre-lox recombination
US5922576A (en) Simplified system for generating recombinant adenoviruses
JP4495588B2 (ja) 安定なアデノウイルスベクターおよびその増殖方法
AU2003271737B2 (en) Means and methods for the production of adenovirus vectors
AU2002218569A1 (en) Complementing cell lines
JP2002507897A (ja) 遺伝子治療で用いるべきヒト組換えアデノウイルス用のパッケージングシステム
Ruzsics et al. Transposon-Assisted Cloning and Traceless Mutagenesis of Adenoviruses: Development of a Novel Vector Based on SpeciesD
US8709778B2 (en) Method of adenoviral vector synthesis
Youil et al. Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
HK1084974B (en) Packaging cells for recombinant adenovirus
Ng et al. Adenoviral vector construction I: mammalian systems
Class et al. Patent application title: COMPLEMENTING CELL LINES Inventors: Ronald Vogels (Linschoten, NL) Menzo Jans Emco Havenga (Alphen A/d Rijn, NL) Majid Mehtall (Plobsheim, FR)
Ng et al. Mammalian Systems
Cultured Epstein-Barr Virus Hybrid− An Adenovirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071001

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110510

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110517

R150 Certificate of patent or registration of utility model

Ref document number: 4749334

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140527

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees